mypeptidesrx puts the treatment goal first

Semaglutide and the kidney question

I arrived at FLOW expecting another weight-loss story. Its main question was much more consequential: could semaglutide reduce major kidney-disease events in people who already had type 2 diabetes and chronic kidney disease?

In FLOW’s 3,533-person trial, the composite outcome combined kidney failure, major loss of kidney filtration and kidney- or cardiovascular-related death. Semaglutide reduced that outcome by 24% relative to placebo (HR 0.76, 95% CI 0.66-0.88). A composite counts several specified events together; the overall reduction cannot be assigned to each event separately.

This paper earns its prominent place for me because the feared outcome changes the discussion. Someone concerned about kidney failure is asking a different question from someone comparing average weight changes. The same molecule can have evidence relevant to both, with different people and measurements behind each answer.

Goal in the margin: fewer major kidney-disease events. FLOW enrolled people with both type 2 diabetes and chronic kidney disease.

Three peptides, several treatment goals

The “my” in mypeptidesrx seems an awkward fit for a universal winner. Personal relevance begins with a goal, then runs into the particulars: the condition being treated, the evidence for that condition and the risks that accompany treatment.

Semaglutide and tirzepatide act on gut-hormone receptors involved in insulin release and appetite; tirzepatide activates both GIP and GLP-1 receptors. The clinical reference on tirzepatide describes that dual action. Tesamorelin takes a different route, stimulating the pituitary’s release of growth hormone. Its approved use concerns excess abdominal fat in adults with HIV-associated lipodystrophy.

For cardiovascular events, semaglutide’s SELECT trial enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. For a direct weight comparison, SURMOUNT-5 tested tirzepatide against semaglutide in 751 adults with obesity without type 2 diabetes. Those are useful destinations to distinguish before choosing a page.

Choose the outcome to examine

• Semaglutide: kidney and cardiovascular outcomes. Begin with FLOW and SELECT, then put the weight result beside them.
• Tirzepatide: glucose control and weight change. Two direct comparisons ask different questions of the same pair of drugs.
• Tesamorelin: visceral fat, blood sugar and diabetes. The benefit concerns a particular fat depot and a defined HIV-related condition.
• Tesamorelin vs semaglutide, and other comparisons. A comparison sheet organised around the treatment goal.

My preferred question names an outcome and a population. “Which peptide is best?” leaves almost everything that matters unstated. The FAQ deals with the questions that tend to get bundled into it.

Adverse effects

A benefit can be substantial and treatment can still be difficult to tolerate. Semaglutide’s safety review describes gastrointestinal effects and increased biliary-disease risk. Tirzepatide’s pooled safety analysis found an increased composite risk of gallbladder or biliary disease. Tesamorelin raises IGF-1, and its longer trial programme leaves questions about much longer exposure.

Several of these results deserve my admiration. I object to summaries that strip away the treatment goal until only a flattering percentage remains. The studies become more useful when the outcome, the people studied and the adverse effects can share the page.

mndvcrnq peptide and miapeptide

The cited literature does not identify either “mndvcrnq peptide” or “miapeptide”. This bibliography therefore leaves both names unresolved.